Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
MDT — frequently asked questions
Is Medtronic plc overvalued?
In our latest published analysis dated 2026-05-12, MDT looks meaningfully undervalued. The price recorded at analysis is 76,8 USD versus our fair value of 95,9 USD; the high endpoint is presented separately as potential value of 114 USD. That implies roughly 24.8% upside to fair value at that date.
Our latest published report, analyzed 2026-05-12, gives MDT a fair value of 95,9 USD and a potential value of 114 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Medtronic plc's archetype; it is a dated research output, not a live price.
Should I buy MDT now?
Our latest published rating for MDT, analyzed 2026-05-12, is Buy. Medtronic plc looks meaningfully undervalued at the analysis-date price of 76,8 USD versus fair value of 95,9 USD; potential value is 114 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for MDT?
The dedicated bear-case section in our report analyzed 2026-05-12 documents Medtronic plc's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is MDT's rating?
Our latest published rating for MDT, analyzed 2026-05-12, is Buy, with a published moat assessment of 9/10 (Wide). It reflects our fair value of 95,9 USD, the potential value of 114 USD, and the price recorded at analysis (76,8 USD).
Affichage de la source anglaise pendant la traduction
Ce rapport n'a pas encore été traduit. Actualisez dans quelques minutes une fois que la file d'attente de traduction aura rattrapé son retard.
§1 RésuméEN
Réponse en 30 secondesBuy
Prix par rapport à la valeur
Cours
$76.82
Juste valeur
$95.89
Valeur potentielle
$113.75
Au
Date de cotation non enregistrée
Pourquoi le scénario peut fonctionner
Bull: Successful launch and rapid adoption of new therapies reignite mid-single-digit top-line growth, driving operating leverage and margin expansion.
Ce qui changerait notre avis
Pipeline Stagnation: Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
Medtronic is a dominant, entrenched player in the global medical devices industry. While near-term growth is sluggish and quarterly earnings are compressed, its immense scale, high switching costs for healthcare providers, and reliable free cash flow easily support a high dividend payout, fitting the classic mature dividend archetype.
Medtronic is a dominant, entrenched player in the global medical devices industry. While near-term growth is sluggish and quarterly earnings are compressed, its immense scale, high switching costs for healthcare providers, and reliable free cash flow easily support a high dividend payout, fitting the classic mature dividend archetype.
Buy. Medtronic's deeply entrenched portfolio and cash generation capabilities are severely undervalued by a market fixated on near-term trailing stagnation.
Présentation de l’entreprise
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
§2 Cas baissierEN
A prolonged period of sluggish top-line growth combined with intense pricing pressure and hospital capital constraints severely compresses operating margins below the 19.5% baseline, threatening Medtronic's reliable free cash flow and forcing a cut to its high dividend payout.
Intense competition and pricing pressure erode gross margins, threatening the dividend growth trajectory and resulting in severe multiple compression.
Comment cette thèse peut échouer
Pipeline Stagnation
Medium
Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
FV impact
-20%
Trigger
12-24 months
Hospital Capital Freeze
Low
Macroeconomic pressures force severe hospital capital constraints and widespread deferral of elective procedures, crushing revenue growth to negative territory.
Signaux d'alerte précoce à surveiller
Les cinq évolutions qui affaibliraient notre thèse d’investissement.
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
Conforme
Hold
Déclencheur: In-line results
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
Manqué
Reassess
Déclencheur: Downside surprise
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
Qualité des résultats
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
Healthcare system capital spending constraints and deferred procedures delay volume recovery.
Positionnement
High dividend payout limits aggressive M&A, forcing reliance on internal R&D and pipeline execution.
§11 Gestion de positionEN
Taille de position
Core holding given mature dividend archetype and low downside risk.
Risque
Re-evaluate if capex/revenue structurally disconnects or if forward revenue estimates drop below 1.5%.
Tranches d'entrée
Niveau
Action
Pourquoi
Current / pullbacks
Tranches de sortie
Niveau
Action
Thesis break
Re-evaluate if capex/revenue structurally disconnects or if forward revenue estimates drop below 1.5%.
§12 Perspectives des investisseursEN
Bull view
Buy
Buy. The current share price fails to credit the immense durability of Medtronic's free cash flow engine, providing a large margin of safety against sluggish top-line growth.
Base view
Buy
The 1.73% implied growth hurdle from the Reverse DCF confirms extreme market pessimism. Our multi-model synthesis relies heavily on structural cash generation to bypass near-term trailing noise.
§14 Recommandation finaleEN
Action
Acheter
Buy. The current share price fails to credit the immense durability of Medtronic's free cash flow engine, providing a large margin of safety against sluggish top-line growth.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Sub-par capital efficiency indicates that elevated capital outlays are failing to produce accretive operating profits. Generating returns below the corporate hurdle rate erodes economic value and restricts capital redeployment toward high-growth medtech innovations, weakening long-term competitive differentiation.
Actuel :6.6% as of 2026-05-12
Alerte siROIC declines below 5.0% over a twelve-month period
Persistent margin degradation reflects an inability to offset customer pricing pressure and medical inflation through cost containment. Compressing operating margins directly reduces free cash flow generation, eliminating bottom-line operating leverage and endangering the company's valuation multiple relative to peers.
Actuel :19.5% for the period ended 2025-04-30
Alerte siOperating margin falls below 19.5% over two consecutive fiscal quarters
Escalating cash commitment to shareholder payouts leaves little cushion against revenuevolatility or unexpected clinical liabilities. Exceeding sustainable cash boundaries forces either an outright dividend reduction or debt-funded shareholder returns, destroying the core defensive income thesis and triggering severe multiple compression.
Major regulatory or clinical setbacks freeze critical product launch cycles in high-margin growth categories. Failing to refresh innovative offerings allows agile competitors to permanently capture market share, undermining premium pricing power and eliminating key anticipated drivers of mid-single-digit top-line acceleration.
Actuel :Active pipeline development programs as of 2026-05-12
Alerte si1 or more formal FDA rejections or Phase 3 clinical trial terminations in Cardiovascular or Diabetes pipelines within a 12-month period
Monitor the threat against the report checkpoints.
Regulatory delays stalling product cycles.
medium
Monitor
Monitor the threat against the report checkpoints.
Warning level: ROIC declines below 5.0% over a twelve-month period. Sub-par capital efficiency indicates that elevated capital outlays are failing to produce accretive operating profits. Generating returns below the corporate hurdle rate erodes economic value and restricts capital redeployment toward high-growth medtech innovations, weakening long-term competitive differentiation.
Warning level: Dividend payout ratio exceeds 90% of free cash flow over an annual period. Escalating cash commitment to shareholder payouts leaves little cushion against revenuevolatility or unexpected clinical liabilities. Exceeding sustainable cash boundaries forces either an outright dividend reduction or debt-funded shareholder returns, destroying the core defensive income thesis and triggering severe multiple compression.
05
Métrique:
Cardiovascular and Diabetes Clinical Approvals
ActuelActive pipeline development programs as of 2026-05-12
Pourquoi c'est important
Warning level: 1 or more formal FDA rejections or Phase 3 clinical trial terminations in Cardiovascular or Diabetes pipelines within a 12-month period. Major regulatory or clinical setbacks freeze critical product launch cycles in high-margin growth categories. Failing to refresh innovative offerings allows agile competitors to permanently capture market share, undermining premium pricing power and eliminating key anticipated drivers of mid-single-digit top-line acceleration.
